DE602006019638D1 - Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen - Google Patents

Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen

Info

Publication number
DE602006019638D1
DE602006019638D1 DE602006019638T DE602006019638T DE602006019638D1 DE 602006019638 D1 DE602006019638 D1 DE 602006019638D1 DE 602006019638 T DE602006019638 T DE 602006019638T DE 602006019638 T DE602006019638 T DE 602006019638T DE 602006019638 D1 DE602006019638 D1 DE 602006019638D1
Authority
DE
Germany
Prior art keywords
dcs
cultured
transwell
populations
blood monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019638T
Other languages
English (en)
Inventor
Donald Drake Iii
David Moe
Conan Li
Heather Fahlenkamp
Guzman Sanchez-Schmitz
Russell Higbee
Robert Parkhill
William L Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VaxDesign Corp
Original Assignee
VaxDesign Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VaxDesign Corp filed Critical VaxDesign Corp
Publication of DE602006019638D1 publication Critical patent/DE602006019638D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4641—Fungal antigens, e.g. Trichophyton, Aspergillus or Candida
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/12—Well or multiwell plates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/20—Material Coatings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/02—Membranes; Filters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/14—Scaffolds; Matrices
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Sustainable Development (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Clinical Laboratory Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602006019638T 2005-12-21 2006-12-21 Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen Active DE602006019638D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75203305P 2005-12-21 2005-12-21
PCT/US2006/049128 WO2007076061A1 (en) 2005-12-21 2006-12-21 A porous membrane device that promotes the differentiation of monocytes into dendritic cells

Publications (1)

Publication Number Publication Date
DE602006019638D1 true DE602006019638D1 (de) 2011-02-24

Family

ID=37963795

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019638T Active DE602006019638D1 (de) 2005-12-21 2006-12-21 Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen

Country Status (9)

Country Link
US (2) US20070178076A1 (de)
EP (2) EP2199384B1 (de)
JP (1) JP2009521228A (de)
AT (2) ATE495238T1 (de)
AU (1) AU2006330951B2 (de)
CA (2) CA2847310A1 (de)
DE (1) DE602006019638D1 (de)
IL (1) IL192090A (de)
WO (1) WO2007076061A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785883B2 (en) 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7785806B2 (en) 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US20070178076A1 (en) * 2005-12-21 2007-08-02 Drake Donald Iii Porous membrane device that promotes the differentiation of monocytes into dendritic cells
WO2007075979A2 (en) 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
EP2409715A1 (de) * 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
WO2010105285A1 (en) * 2009-03-17 2010-09-23 The Heart Research Institute Method of cell differentiation and uses therefor in screening, diagnosis and therapy
EP2529274B1 (de) * 2010-01-29 2014-10-08 Canon Nanotechnologies, Inc. Nanoimprintverfahren zur herstellung von nanopartikeln
WO2013134464A1 (en) 2012-03-07 2013-09-12 Children's Medical Center Corporation Tissue constructs and uses thereof
US9423234B2 (en) 2012-11-05 2016-08-23 The Regents Of The University Of California Mechanical phenotyping of single cells: high throughput quantitative detection and sorting
FR3045664A1 (fr) 2015-12-17 2017-06-23 Oreal Membrane pour tissu reconstruit comprenant des pores de plusieurs diametres
EP3510143B1 (de) * 2016-09-08 2023-03-01 Sanofi Pasteur Vaxdesign Corp. Neonatales biomimetisches (nmimic) in-vitro-modell und verfahren zur verwendung davon
KR101986092B1 (ko) * 2016-09-13 2019-06-05 대한뉴팜(주) 유두진피 섬유아세포의 고순도 분리 방법
US11175282B2 (en) 2017-06-26 2021-11-16 Biohope Scientfic Solutions For Human Health S.L. Method for predicting and monitoring clinical response to immunomodulatory therapy
CN112221543B (zh) * 2019-07-15 2024-05-10 京东方科技集团股份有限公司 细胞片层转移器件、运输装置和转移细胞片层的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160490A (en) * 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US5827641A (en) * 1992-11-13 1998-10-27 Parenteau; Nancy L. In vitro cornea equivalent model
US5695996A (en) * 1994-09-23 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Artificial organ culture system
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5739001A (en) * 1996-10-29 1998-04-14 E. I. Du Pont De Nemours And Company Solid phase cell-based assay
US6177282B1 (en) * 1997-08-12 2001-01-23 Mcintyre John A. Antigens embedded in thermoplastic
DE69840739D1 (de) * 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
JP2003513988A (ja) * 1999-11-12 2003-04-15 ファイブローゲン、インコーポレーテッド ワクチンに含まれる組換えゼラチン
EP1231836A4 (de) * 1999-11-17 2004-06-02 Univ Rochester Menschliches ex vivo immunsystem
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002062971A1 (en) * 2001-02-07 2002-08-15 Korea Atomic Energy Research Institute Method of isolating epithelial cells, method of preconditioning cells, and methods of preparing bioartificial skin and dermis with the epithelial cells or the preconditioned cells
WO2003026712A1 (fr) * 2001-09-25 2003-04-03 Japan Science And Technology Agency Procede de formation de membrane basale, procede d'elaboration d'echantillon de membrane basale, tissu artificiel reconstitue utilisant cet echantillon, et procede d'elaboration de ce tissu
FR2833271B1 (fr) * 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
GB0130789D0 (en) * 2001-12-21 2002-02-06 King S College London Application of spores
CA2480011A1 (en) * 2002-03-18 2003-12-04 Sciperio, Inc. Dentritic cell nodes
ATE538378T1 (de) * 2002-04-11 2012-01-15 Cylex Inc Verfahren zur überwachung der immunantwort und vorhersage der klinischen resultate bei empfängern von transplantaten
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
AU2003275421A1 (en) * 2002-10-03 2004-04-23 Andrea Bottaro Three-dimensional peripheral lymphoid organ cell cultures
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US20070141552A1 (en) * 2004-04-28 2007-06-21 Warren William L Automatable artificial immune system (AIS)
US20060275270A1 (en) * 2004-04-28 2006-12-07 Warren William L In vitro mucosal tissue equivalent
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US8071373B2 (en) * 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
EP1758985B1 (de) * 2004-04-28 2015-06-03 Sanofi Pasteur VaxDesign Corporation Künstliches immunsystem: verfahren zur herstellung und verwendung
WO2007075979A2 (en) * 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
US20070178076A1 (en) * 2005-12-21 2007-08-02 Drake Donald Iii Porous membrane device that promotes the differentiation of monocytes into dendritic cells
EP2409715A1 (de) * 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
EP2420516A1 (de) * 2007-07-06 2012-02-22 Sanofi Pasteur VaxDesign Corporation Schnelle Erzeugung von T-Zellen-unabhängigen Antikörper-Reaktionen auf T-Zellen-abhängige Antigene

Also Published As

Publication number Publication date
EP2199384A1 (de) 2010-06-23
CA2847310A1 (en) 2007-07-05
AU2006330951B2 (en) 2012-04-05
CA2634119A1 (en) 2007-07-05
EP1963491A1 (de) 2008-09-03
EP2199384B1 (de) 2011-11-02
JP2009521228A (ja) 2009-06-04
US20070178076A1 (en) 2007-08-02
US20100105135A1 (en) 2010-04-29
ATE531793T1 (de) 2011-11-15
IL192090A0 (en) 2008-12-29
EP1963491B1 (de) 2011-01-12
IL192090A (en) 2012-01-31
CA2634119C (en) 2015-02-24
AU2006330951A1 (en) 2007-07-05
ATE495238T1 (de) 2011-01-15
WO2007076061A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
ATE495238T1 (de) Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen
Shiota et al. Development of the fetal mouse palate in suspension organ culture
JP5795699B2 (ja) 人工免疫システム：作製および使用方法
US11590214B2 (en) Antigen presenting scaffolds for immune-cell manipulation
Raha et al. Disruption of de novo fatty acid synthesis via acetyl‐CoA carboxylase 1 inhibition prevents acute graft‐versus‐host disease
CN1423523A (zh) 来自人体内的免疫系统
DK1292321T3 (da) Fremgangsmåde til at forøge klasse 1 præsentation af exogene antigener gennem humane dendritiske celler
Nakamura et al. Macrophages regulate expression of α1, 2-fucosyltransferase genes in human endometrial epithelial cells
CN101314764A (zh) 一种体外扩增自然杀伤细胞的方法
Livingston et al. CD4 T-helper cell cytokine phenotypes and antibody response following tetanus toxoid booster immunization
Lanzinger et al. Ambivalent effects of dendritic cells displaying prostaglandin E 2‐induced indoleamine 2, 3‐dioxygenase
Chiu et al. The innate pulmonary granuloma: characterization and demonstration of dendritic cell recruitment and function
Curnow et al. In vitro developmental potential of macaque oocytes, derived from unstimulated ovaries, following maturation in the presence of glutathione ethyl ester
Anton et al. Generation of dendritic cells from peripheral blood adherent cells in medium with human serum
Adkins et al. The primary responses of murine neonatal lymph node CD4+ cells are Th2‐skewed and are sufficient for the development of Th2‐biased memory
Angel et al. Comprehensive analysis of MHC‐II expression in healthy human skin
AU2003288212A1 (en) Method to measure a T cell response and its uses to qualify antigen-presenting cells
US20230138095A1 (en) Scaffolds with stabilized mhc molecules for immune-cell manipulation
DE60043781D1 (de) Verwendung allogener zelllinien zur beladung antigen-präsentierender zellen zur auslösung von immunantworten
Sjaastad et al. Reduced T Cell Priming in Microbially Experienced “Dirty” Mice Results from Limited IL-27 Production by XCR1+ Dendritic Cells
WO2007065439A1 (en) Method for generating dendritic cells employing decreased temperature
Delles et al. A simple method for the purification of human peripheral blood antigen presenting cells (dendritic cells, monocytes/macrophages, and B lymphocytes)
Toulmin et al. Type II alveolar cells with constitutive expression of MHCII and limited antigen presentation capacity contribute to improved respiratory viral disease outcomes
Jones Assays on the influence of biomaterials on allogeneic rejection in tissue engineering
Majai et al. Autologous apoptotic neutrophils inhibit inflammatory cytokine secretion by human dendritic cells, but enhance Th1 responses

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1963491

Country of ref document: EP

Representative=s name: SCHWABE SANDMAIR MARX, 81677 MUENCHEN, DE

R097 No opposition filed against granted patent, or epo opposition proceedings concluded without decision

Ref document number: 1963491

Country of ref document: EP

Effective date: 20111013